As of 2025-03-16, the Relative Valuation of Keros Therapeutics Inc (KROS) is (174.84) USD. This relative valuation is based on P/E multiples. With the latest stock price at 11.58 USD, the upside of Keros Therapeutics Inc based on Relative Valuation is -1609.8%.
The range of the Relative Valuation is (144.67) - (221.35) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 31.3x - 47.9x | 41.2x |
| Forward P/E multiples | 26.9x - 48.6x | 34.5x |
| Fair Price | (144.67) - (221.35) | (174.84) |
| Upside | -1349.3% - -2011.5% | -1609.8% |
| Date | P/E |
| 2025-03-03 | -2.43 |
| 2025-02-28 | -2.40 |
| 2025-02-27 | -2.38 |
| 2025-02-26 | -2.37 |
| 2025-02-25 | -2.36 |
| 2025-02-24 | -2.34 |
| 2025-02-21 | -2.39 |
| 2025-02-20 | -2.39 |
| 2025-02-19 | -2.30 |
| 2025-02-18 | -2.29 |
| 2025-02-14 | -2.23 |
| 2025-02-13 | -2.20 |
| 2025-02-12 | -2.21 |
| 2025-02-11 | -2.23 |
| 2025-02-10 | -2.27 |
| 2025-02-07 | -2.35 |
| 2025-02-06 | -2.49 |
| 2025-02-05 | -2.41 |
| 2025-02-04 | -2.38 |
| 2025-02-03 | -2.41 |
| 2025-01-31 | -2.47 |
| 2025-01-30 | -2.54 |
| 2025-01-29 | -2.46 |
| 2025-01-28 | -2.45 |
| 2025-01-27 | -2.48 |
| 2025-01-24 | -2.56 |
| 2025-01-23 | -2.60 |
| 2025-01-22 | -2.47 |
| 2025-01-21 | -2.47 |
| 2025-01-17 | -2.35 |
| 2025-01-16 | -2.28 |
| 2025-01-15 | -2.26 |
| 2025-01-14 | -2.70 |
| 2025-01-13 | -2.78 |
| 2025-01-10 | -3.15 |
| 2025-01-08 | -3.22 |
| 2025-01-07 | -3.43 |
| 2025-01-06 | -3.39 |
| 2025-01-03 | -3.49 |
| 2025-01-02 | -3.45 |
| 2024-12-31 | -3.43 |
| 2024-12-30 | -3.39 |
| 2024-12-27 | -3.55 |
| 2024-12-26 | -3.64 |
| 2024-12-24 | -3.62 |
| 2024-12-23 | -3.71 |
| 2024-12-20 | -3.69 |
| 2024-12-19 | -3.66 |
| 2024-12-18 | -3.71 |
| 2024-12-17 | -3.90 |